SNY241220C57500
- 0.01
- 0.000.00%
Sanofi Newsroom
Express News | CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
European Equities Traded in the US as American Depositary Rise in Wednesday Trading
Express News | CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Sanofi (SNY.US) successfully introduced the TL1A monoclonal antibody for the treatment of inflammatory bowel disease in a Phase IIb study with an investment of 1.5 billion dollars.
In October 2023, Sanofi (SNY.US) reached an agreement with Teva for the development and commercialization of the drug, with an upfront payment of 0.5 billion dollars and milestone payments of up to 1 billion dollars.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn Into More Strength?
Sanofi and Teva's Duvakitug Meets Primary Endpoints in Phase IIb Trial
Promising Potential: Sanofi's Strong Pipeline and Strategic Market Focus Drive Buy Rating
Why These Two Pharma Stocks Are Surging
Top Gap Ups and Downs on Tuesday: TEVA, NET, SAN and More
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Teva Soars 21%, Sanofi Gains on Strong Trial Results for IBD Treatment
Correction to Teva Articles
Sanofi Up Over 7%, On Track for Largest Percent Increase Since December 2022 -- Data Talk
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Teva, Cloudflare, Sanofi: Trending Tickers
Sanofi (SNYNF) Gets a Hold From J.P. Morgan
Sanofi (SNYNF) Gets a Buy From Jefferies
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading